

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/467,928	12/21/1999	DAVID GAILLAC	017753-120	2965	
21839 759	90 10/06/2003		EXAM	INER	
BURNS DOANE SWECKER & MATHIS L L P POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404			PARKIN, JI	PARKIN, JEFFREY S	
			ARTIQUE	DARED MEDICER	
			ART UNIT	PAPER NUMBER	
			1648		

DATE MAILED: 10/06/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
¥	09/467,928	GAILLAC ET AL.				
Office Action Summary	Examin r	Art Unit				
	Jeffrey S. Parkin, Ph.D.	1648				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with	the correspondenc address				
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	136(a). In no event, however, may a reply within the statutory minimum of thirty (will apply and will expire SIX (6) MONTHE, cause the application to become ABAN	ly be timely filed 30) days will be considered timely. IS from the mailing date of this communication. NDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on 28.	<u>April 2003</u> .					
2a) This action is FINAL . 2b) ⊠ Th	nis action is non-final.					
3) Since this application is in condition for allows closed in accordance with the practice under Disposition of Claims	•	• •				
. 4)⊠ Claim(s) <u>1-12</u> is/are pending in the application	1 .					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-12</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/o	or election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examine	er.	·				
10)☐ The drawing(s) filed on is/are: a)☐ acce	pted or b) objected to by the	e Examiner.				
Applicant may not request that any objection to th						
11) The proposed drawing correction filed on		approved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.						
12) ☐ The oath or declaration is objected to by the Ex	kaminer.					
Pri rity under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C. §	119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
Certified copies of the priority document						
2. Certified copies of the priority document						
 3. Copies of the certified copies of the prio application from the International Bu * See the attached detailed Office action for a list 	reau (PCT Rule 17.2(a)).	_				
14) ☐ Acknowledgment is made of a claim for domest	·					
a) The translation of the foreign language pro	, ,					
15) Acknowledgment is made of a claim for domest						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _	5) Notice of Info	mmary (PTO-413) Paper No(s) ormal Patent Application (PTO-152)				

Serial No.: 09/467,928 Docket No.: 017753-120

Applicants: Gaillac, D., and M. Koehl Filing Date: 12/21/99

Response to Amendment

37 C.F.R. § 1.114

1. A request for continued examination under 37 C.F.R. § 1.114, including the fee set forth in 37 C.F.R. § 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 C.F.R. § 1.114, and the fee set forth in 37 C.F.R. § 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 C.F.R. § 1.114. Applicants' submission filed on 28 April, 2003, has been entered.

5

10

15

20

25

Status of the Claims

2. Acknowledgement is hereby made of receipt and entry of the amendment submitted 28 April, 2003, wherein claims 13-15 were canceled without prejudice or disclaimer and claims 1-12 amended. Claims 1-12 are pending in the instant application.

35 U.S.C. § 112, Second Paragraph

3. Claims 1-12 stand rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims remain vague and indefinite for reciting claim limitations employing the term "about". Contrary to applicants' assertion, the phrase fails to clearly set forth the metes and bounds of the patent protection desired. For instance, claim 1 contains the phrases "about -5°C and +50°C" and "about 5 and about 9", which are vague and indefinite since the precise parameters of the claimed invention are not readily manifest. Appropriate correction is still required.

Serial No.: 09/467,928 Applicants: Gaillac, D., and M. Koehl

35 U.S.C. § 103(a)

4. The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

5

10

15

20

25

30

35

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

5. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. § 103@ and potential 35 U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103(a).

6. Claims 1-12 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Kameyama et al. (1990) in view of Gao and Wilson (2001). Applicants' arguments have been considered but are not deemed to be persuasive. As previously set forth, Kameyama and colleagues disclose methods for the inactivation of enveloped viruses that are contaminating a protein-containing composition by treating said compositions with 0.3% (w/v) TNBP and 1% (w/v) Tween 80 (see Examples 1 and 2, pp. 7 and 9, respectively). This

Serial No.: 09/467,928 Applicants: Gaillac, D., and M. Koehl

procedure resulted in the inactivation of various enveloped viruses (e.g., VSV or Sindbis virus) without adversely affecting the infectivity of a non-enveloped virus (e.g., Echo virus). Various routine experimental parameters are also described (e.g., % of TNBP, % of detergent, temperature ranges, conductivity ranges, pH ranges, etc.). Gao and Wilson (2001) disclose the medical importance of adenoviral vectors and their use in therapeutic compositions.

5

10

15

20

25

While Kameyama et al. (1990) do not disclose the inactivation of enveloped viruses in an adenoviral-containing preparation, nevertheless, it would have been prima facie obvious to one having ordinary skill in the art at the time the invention was made to subject viral preparations comprising both enveloped viruses and non-enveloped adenoviruses to the aforementioned treatments, since this would provide a means of ensuring the safety of non-enveloped adenoviral vector preparations for any one of a number of purposes such as gene therapy or diagnostic applications. Kameyama et al. (1990) state (p. 3, 1. 13-25) that "There is no particular limitation posed on the protein-containing liquid composition to which the method of the present invention is Examples thereof include plasma or tissue extracts, solutions comprising a fraction obtained by treating plasma or tissue extract by various fractionation methods, culture broths obtained by culturing a gene recombinant host or tissue and commercially available protein preparations (in a liquid form) or their solutions." Thus, both the motivation and a reasonable expectation of success were present in the prior art.

Correspondence

7. Correspondence related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Official communications should be directed toward one of the following Group 1600 fax numbers: (703)

Serial No.: 09/467,928 Applicants: Gaillac, D., and M. Koehl

308-4242 or (703) 305-3014. Informal communications may be submitted directly to the Examiner through the following fax number: (703) 308-4426. Applicants are encouraged to notify the Examiner prior to the submission of such documents to facilitate their expeditious processing and entry.

8. Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (703) 308-2227. The examiner can normally be reached Monday through Thursday from 8:30 AM to 6:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisors, James Housel or Laurie Scheiner, can be reached at (703) 308-4027 or (703) 308-1122, respectively. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Respectfully,

5

10

15

Jeffrey S. Parkin, Ph.D.

Patent Examiner Art Unit 1648

06 September, 2003